SHMT2 and cancer: Therapies that target the single-carbon metabolic pathway, such as serine hydroxymethyltransferases (SHMT1 and SHMT2) inhibition, the key enzymes that convert serine to glycine, and lowering entry of monocarbons to the tetrahydrofolate (THF) cycle, are promising for anti-cancer therapies.